Picture of Protara Therapeutics logo

TARA — Protara Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Protara Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

* Protara Therapeutics Inc  TARA.OQ   TARA.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 1 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Protara Therapeutics Inc
is
for a loss of 52 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Protara
Therapeutics Inc is 23.00​, above​ its last closing price
of $2.34. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.96       -0.80      -0.45     Beat    43.8
 Jan. 1 2024   -0.86                  -0.97             -5.4
 Dec. 31 2023              -0.92      -0.90     Beat    1.9​
 Jan. 1 0001   -1.04       -0.98      -0.87     Beat    11.2
 ​​Jun.        -0.88       -0.87      -1.00     Missed  -14.3
 30 2023                                                
 Mar. 31 2023  -0.91       -0.88      -0.80     Beat    8.8​
 Dec. 31 2022              -0.75      -1.55     Missed  -106.7
 Jan. 1 0001   -0.77       -0.76      -0.68     Beat    10.1
 This summary was machine generated October 30 at 13:23 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Protara Therapeutics

See all news